drugset / Trial / NCT03540225

Vaginal Progesterone for the Prevention of Preterm Birth in Twins

NCT03540225

Phase 3 Withdrawn Chiu Yee Liona Poon
RandomizedFactorialTriple-blindPrevention

Summary

This trial is a randomised, multi-centre, 2 x 2 factorial designed pilot trial with two factors of 200mg vs. 400mg progesterone self-administered daily from 11-14 weeks' gestation vs. 20-24 weeks' gestation, to compare the median gestational age (in days) at delivery between the comparison groups.

Timeline

Start
2020-04
Primary completion
2022-04
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Progesterone Other / unclassified 200 mg Intravenous
Subject Progesterone Other / unclassified 400 mg Intravenous

Indications